Catalog No.
DHC98599
Description
Lorvotuzumab mertansine is an ADC consisting of an NCAM-directed antibody and DM1, a potent derivative of maytansine, used for the study of several solid tumors and hematological tumors.
Species reactivity
Human
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
NCAM
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MGN901, huN901-DM1
Clone ID
Lorvotuzumab mertansine
Note
For research use only. Not suitable for clinical or therapeutic use.
Immunoconjugates against solid tumors: mind the gap., PMID:21368753
ADME of antibody-maytansinoid conjugates., PMID:22875610
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany., PMID:22909934
Drug-conjugated antibodies for the treatment of cancer., PMID:23173552
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets., PMID:23239665
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients., PMID:23721099
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program., PMID:23798344
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma., PMID:24389179
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models., PMID:24492307
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies., PMID:24708159
Novel formulations and new mechanisms of delivering chemotherapy., PMID:24857128
Monoclonal antibodies in myeloma., PMID:26452191
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates., PMID:26927803
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors., PMID:26961907
Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis., PMID:27935326
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML., PMID:28321813
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease., PMID:28341109
Emerging antibody-drug conjugates for treating lymphoid malignancies., PMID:28792782
Advances in antibody therapeutics targeting small-cell lung cancer., PMID:29790694
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma., PMID:30340993
NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target., PMID:31477684
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study., PMID:32914879
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer., PMID:34942494
For research use only. Not for human or drug use.
